Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer

Chenglou Zhu; Mingxu Da; Yaoqi Li; Lingzhi Peng

doi:10.3389/fonc.2024.1425572

Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer

Front Oncol. 2024 Sep 5:14:1425572. doi: 10.3389/fonc.2024.1425572. eCollection 2024.

Authors

Chenglou Zhu^#¹, Mingxu Da^#^{1

2}, Yaoqi Li², Lingzhi Peng^{1

2}

Affiliations

¹ The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
² Department of Surgical Oncology, Gansu Provincial Hospital, Lanzhou, China.

^# Contributed equally.

Abstract

Background: The efficacy of a regimen combining Tegafur, Gimeracil and Oteracil Potassium Capsules (S-1), oxaliplatin (SOX) with trastuzumab and tislelizumab chemotherapy for advanced gastric cancer (GC) has not been reported.

Case summary: A 56-year-old male was diagnosed with GC combined with peripheral lymph node metastasis. The patient received neoadjuvant chemotherapy, including SOX, tislelizumab and trastuzumab. After 4 cycles of chemotherapy, the tumor shrank significantly, and radical surgery was performed with good clinical results. To date, the patient has been followed up for 6 months with no significant side effects.

Conclusion: In this study, the patient received combination chemotherapy with SOX trastuzumab and tislelizumab and successfully underwent radical surgery with good clinical outcomes. Combined SOX with trastuzumab and tislelizumab may be an effective neoadjuvant chemotherapy regimen.

Keywords: SOX regimen; advanced gastric cancer; neoadjuvant chemotherapy; tislelizumab; trastuzumab.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Natural Science Foundation of Gansu Province (grant number 23JRRA1317, 23JRRA1782).